Tabelecleucel in Post-transplant Epstein-Barr Virus-Associated Lymphoproliferative Disease: Patient and Oncologist Perspectives.

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-05-30 DOI:10.1007/s12325-025-03246-z

Antonio Perez-Martinez, Anarbella Lastra Rodrigo, Esther Ramos Boluda, Berta Gonzalez Martinez, Alida Alcolea Sánchez, Francisco Hernandez Oliveros

引用次数: 0

Abstract

This article is coauthored by the parents of a young patient and the medical team who cared for her.Together, they recount their shared experience with tabelecleucel, a novel therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV + PTLD). The patient's parents offer a deeply personal perspective, reflecting on several years of struggle marked by unwavering hope and trust in the medical professionals who have supported their daughter throughout her journey. The pediatric hemato-oncologist who advocated for the use of tabelecleucel described the case as unique worldwide.Their joint testimony tells the remarkable story of how tabelecleucel, despite an initially unclear biological rationale, achieved a reversal of a severe case of EBV + PTLD that had progressed to a point considered beyond recovery and associated with a dire prognosis.

查看原文本刊更多论文

tabeleucel在移植后Epstein-Barr病毒相关淋巴增生性疾病中的应用：患者和肿瘤学家的观点。

这篇文章是由一位年轻病人的父母和照顾她的医疗团队共同撰写的。他们一起讲述了他们使用tabelecleucel的共同经历，tabelecleucel是一种治疗eb病毒相关移植后淋巴细胞增生性疾病（EBV + PTLD）的新疗法。病人的父母提供了一个深刻的个人观点，反映了几年的斗争，标志着坚定不移的希望和对医疗专业人员的信任，他们在整个过程中一直支持着他们的女儿。儿科血液肿瘤学家谁主张使用台布莱索描述的情况下，世界上独一无二的。他们的联合证词讲述了一个引人注目的故事，即尽管最初的生物学原理不明确，但tabelecleucel如何逆转了一个严重的EBV + PTLD病例，该病例已经发展到无法恢复的程度，并伴有可怕的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.